CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
DUBLIN, Ireland and TREVOSE, Pa., May 25, 2017 -- Strongbridge Biopharma plc (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will present at the Jefferies 2017 Global Healthcare Conference, taking place June 6-9 at the Grand Hyatt in New York City.
Matthew Pauls, president and chief executive officer of Strongbridge Biopharma, will provide a corporate overview on Friday, June 9 at 10:30 a.m. ET. The presentation will be webcast live and archived on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.
About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's first commercial product is KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis. KEVEYIS has orphan drug exclusivity status in the U.S. through August 7, 2022. In addition to establishing this neuromuscular disease franchise, the Company has a clinical-stage pipeline of therapies for rare endocrine diseases. Strongbridge's lead compounds include RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and veldoreotide, a next-generation somatostatin analog being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both RECORLEV and veldoreotide have received orphan designation from the U.S. Food and Drug Administration and the European Medicines Agency. For more information, visit www.strongbridgebio.com.
Contacts: Corporate and Media Relations Elixir Health Public Relations Lindsay Rocco +1 862-596-1304 [email protected] Investor Relations The Trout Group Marcy Nanus +1 646-378-2927 [email protected] USA 900 Northbrook Drive Suite 200 Trevose, PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389
